2002:TSETELCON RF PHARMACEUTICAL. Inc. Analysis

Technical outlook: TELCON RF PHARMACEUTICAL is trading at 785 KRW, well below its 20‑day SMA of 803.65 and far under the 50‑day SMA of 907.32, indicating a bearish price environment. The 14‑day RSI sits at 44, suggesting neither overbought nor oversold conditions, while the MACD line (-48.31) remains negative but the histogram (+3.72) hints at a tentative bullish crossover. Volume is on a decreasing trend, and volatility over the past 30 days is extremely high at 64%, underscoring erratic price swings. Support at 685 KRW and resistance near 945 KRW frame the near‑term trading range, with the current price perched just above support.
Fundamental outlook: The company reports a massive revenue growth of 37% yet suffers from negative operating (‑0.09%) and profit margins (‑76.7%), a negative ROE (‑33.9%) and a debt‑to‑equity ratio of 33.4, reflecting a precarious balance sheet. Cash holdings (≈40 bn KRW) are outweighed by debt (≈34 bn KRW), and free cash flow is positive but operating cash flow is negative. The DCF‑derived fair value of ~3,334 KRW versus the market price of 785 KRW points to a deep undervaluation, but the lack of earnings (PE 0) and zero dividend make the upside speculative. Overall, the stock sits in a high‑volatility, low‑beta (0.49) profile with a historic max drawdown of –82%, suggesting substantial risk despite the valuation gap.